Abstract

OBJECTIVE: The idea behind switch therapy is that antibiotic treatment should be changed from the parenteral to another suitable route (usually oral) as soon as the patient's condition allows. This option is cost-effective in terms of both acquisition costs (oral antibiotics are less expensive than their parenteral counterparts) and indirect costs, and patients may be discharged home sooner. This not only releases hospital beds but is also popular with patients and has other advantages. There are relatively few formal clinical trials, most often using oral third-generation cephalosporins and fluoroquinolones; these agents at present seem the most appropriate to use after parenteral antibiotics have been stopped (usually after 2 to 3 days). Logistic aspects are important, and close collaboration is required between pharmacists, physicians and microbiologists. Further trials are needed in specific patient groups and with other antibiotic regimens to validate the efficacy of switch therapy.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.